Fox Rothschild's Marc Wagner on how 503A pharmacies and 503B outsourcing facilities fill drug supply gaps — from COVID injectables to GLP-1s.

Fox Rothschild's Marc Wagner on why scaling drug production is so slow — overseas API sourcing, supplier qualification, and FDA site approvals that take years.

Waiting for perfect data before deploying AI is a trap — and why 60-70% accuracy is often good enough to start.

Fox Rothschild's Marc Wagner on why the FDA counts 70 drugs in shortage while ASHP counts 188 — and what's driving the gap.

Pharma's chain of custody model is migrating into food and consumer goods — and becoming a cross-industry differentiator.

Pharma logistics are overqualified by design — and how agentic AI can now optimize across thousands of lanes in days, not months.

Pharma AI adoption fails not because of the technology — but because organizations deploy tools before they're ready to use them.

FDA is launching the Rare Disease Framework Initiative, aiming to tailor drug development and review requirements to the realities of small patient populations.